The current global market for vaccines that contain a pertussis component exceeds $4.5 billion per year. Within this market, approximately $1B in sales is attributable to adult and adolescent vaccines and $3.5B to the pediatric market.

Since approval in 2005, sales of adult and adolescent acellular pertussis vaccines have grown rapidly, with nearly $1B in sales in 2015. Sales for adult and adolescent pertussis vaccines, the first target indication for BPZE1, are expected to exceed $2B by 2022.

Copyright 2013-2017 ILiAD Biotechnologies